NASDAQ: MTEX · Life Sciences · 5 alerts · CIK 1056358
Share price
$3.76Close, Nov 16
Market cap
$7.26M
Shares outstanding
1.93MLatest SEC cover page
Sector
Life Sciences
Industry
Medicinal Chemicals & Botanical ProductsSIC 2833
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Mannatech Inc filings on SEC EDGAR ↗
Mannatech reported Q3 2026 net sales of $24.9 million, a 14.6% decrease year-over-year on a constant dollar basis. While net income rose to $8.9 million ($4.61 per diluted share), this was driven by a one-time $10.9 million non-cash income tax benefit rather than operating performance, as the company recorded a pre-tax loss of $2.0 million.
For the nine months ended September 30, 2026, Mannatech reported net sales of $76.4 million and a net income of $10.9 million, a significant recovery from a $3.9 million net loss in the prior year period. This improvement was primarily driven by a $10.5 million income tax benefit and reduced operating expenses, despite a decline in overall net sales.
Mannatech, Inc. dismissed BDO USA, P.C. as its independent registered public accounting firm and appointed CBIZ CPAs P.C. as its new auditor for the fiscal year ending December 31, 2026. The company noted that BDO's 2025 audit report included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
Mannatech, Inc. dismissed BDO USA, P.C. as its independent registered public accounting firm and appointed CBIZ CPAs P.C. as its new auditor, effective October 15, 2026. The company noted that BDO's 2025 audit report included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern, though there were no reported disagreements on accounting principles or practices.